AlphaMark Advisors LLC Raises Stock Position in Pfizer Inc. (NYSE:PFE)

AlphaMark Advisors LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 61.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,703 shares of the biopharmaceutical company’s stock after purchasing an additional 650 shares during the period. AlphaMark Advisors LLC’s holdings in Pfizer were worth $48,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of PFE. Olistico Wealth LLC purchased a new stake in Pfizer during the second quarter worth about $25,000. Creekmur Asset Management LLC acquired a new position in shares of Pfizer during the fourth quarter worth about $32,000. Trivant Custom Portfolio Group LLC grew its position in shares of Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 600 shares in the last quarter. Tennessee Valley Asset Management Partners acquired a new position in shares of Pfizer during the fourth quarter worth about $36,000. Finally, DiNuzzo Private Wealth Inc. acquired a new position in shares of Pfizer during the fourth quarter worth about $37,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. BMO Capital Markets reissued an “outperform” rating and set a $36.00 price objective (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Wells Fargo & Company upped their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Finally, Barclays upped their price target on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Stock Performance

Shares of PFE stock traded down $0.17 during trading hours on Thursday, hitting $28.71. The stock had a trading volume of 28,404,433 shares, compared to its average volume of 39,500,234. The firm has a market capitalization of $162.69 billion, a PE ratio of -478.42, a PEG ratio of 0.99 and a beta of 0.69. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $37.19. The stock’s 50 day moving average is $28.75 and its 200 day moving average is $27.89. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. During the same quarter in the prior year, the business earned $0.67 earnings per share. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. As a group, research analysts forecast that Pfizer Inc. will post 2.68 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.85%. The ex-dividend date is Friday, July 26th. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.